Genmab — Januar 2026
-
EGFR x c-MET is already a crowded space and Genmab now also have MCLA-129 from Merus, an EGFRxc-MET Biclonics. Not sure they are going to keep that one, as the tox profile is not great, but it is a large trial that has been going since 2021, so i think we can expect a decision soon after Genmab fully takes control at Merus.
-
For me the most interesting is that they just opened a new Petosemtamab trial in NSCLC. We have not seen NSCLC data in public yet i believe, but Genmab will have seen it. Timing coincides. My best guess at this moment would be that Genmab goes with Peto for lung cancer.
-
FDA approves daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-daratumumab-and-hyaluronidase-fihj-bortezomib-lenalidomide-and-dexamethasone-newly
-
Genmabs Darzalex Faspro godkendt til kombinationsbehandling af myelomatose https://proinvestor.com/investornyt/1407741/genmabs-darzalex-faspro-godkendt-til-kombinationsbehandling-af-myelomatose
-
Enig. En hurtig gevinsthjemtagning og mulighed for supplering, når den ryger tilpas ned i bunden af kanalen (igen-igen).
-
on the EGFR x cMet crowded space - Two more companies try to outdo Rybrevant https://www.oncologypipeline.com/apexonco/two-more-companies-try-outdo-rybrevant
-
H.C. Wainwright has reiterated a Buy rating and $39.00 price target on Genmab A/S (NASDAQ:GMAB) following FDA approval of DARZALEX FASPRO for newly-diagnosed multiple myeloma patients.
https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-genmab-stock-at-39-price-target-93CH-4469885 -
an extra arm in the original Petosemtamab trial for Colorectal Cancer with FOLFOX chemo https://clinicaltrials.gov/study/NCT03526835?tab=history&a=6&b=7#version-content-panel they now also mention Esophageal Cancer separately from
Gastroesophageal-junction Cancer -
I think they just had forgotten to mention this as an included condition as Esophageal Cancer is also mentioned as a closed arm. Thay have added the info that "Enrollment is currently being explored in mCRC (RAS/RAF wild type) patients in the 3L/4L/5L" (i.e.metastatic colorectal cancer). All other arms seem to be closed.
-
EGFR x cMet - The line-up is revealed to include Merck & Co and J&J itself. https://www.oncologypipeline.com/apexonco/node/1874
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind